US Initiates Section 301 Trade Investigation into Germany Over Pharmaceutical Pricing

The United States has launched a formal Section 301 investigation into Germany, accusing the European nation of persistently underpaying for innovative pharmaceutical products. The probe, announced on June 19, 2026, opens the door for potential retaliatory tariffs on German goods. This marks an escalation in trade tensions between the two allies, with the U.S. Trade Representative’s office citing what it describes as unfair pricing practices that disadvantage American pharmaceutical companies.

The investigation focuses on Germany’s healthcare pricing policies, which U.S. officials argue systematically undervalue new, patented drugs developed by U.S. firms. Under Section 301 of the Trade Act of 1974, the U.S. can impose tariffs or other trade restrictions on countries found to engage in discriminatory or unfair trade practices. The probe is expected to examine Germany’s drug reimbursement mechanisms and their impact on market access for U.S. pharmaceuticals.

This move follows similar U.S. trade actions against other countries and reflects the Biden administration’s continued focus on protecting American intellectual property and ensuring fair market conditions. If the investigation finds Germany in violation, it could lead to tariffs on a wide range of German exports, including automobiles, machinery, and chemicals, which are key sectors of the German economy. The timing is sensitive, as Germany and the broader European Union are already navigating trade disputes with the U.S. over steel and aluminum tariffs, as well as digital services taxes.

German officials have expressed disappointment with the probe, arguing that its healthcare system is designed to ensure affordable access to medicines for its citizens. Berlin has signaled a willingness to engage in negotiations to avoid a full-blown trade war, but also warned it would consider countermeasures if the U.S. imposes tariffs. The European Commission, which oversees EU trade policy, is expected to monitor the situation closely and may intervene on Germany’s behalf.

The pharmaceutical sector is a major area of economic competition and cooperation between the U.S. and Germany, with companies from both countries holding significant market shares globally. The outcome of the investigation could have far-reaching implications for drug pricing, innovation, and transatlantic trade relations. Stakeholders in the industry are calling for dialogue to resolve the dispute without disrupting supply chains or patient access to medicines.